Literature DB >> 9817113

Adaptation and validation of the SF-36 Health Survey for use in Australia.

R W Sanson-Fisher1, J J Perkins.   

Abstract

This article reports on the process undertaken to adapt the U.S. version of the SF-36 to an Australian setting. In addition, the results of psychometric testing, using the International Quality of Life Assessment (IQOLA) Project process and standards, is also reported. The adaptation process involved a number of steps including: a series of forward and backward translations; ratings of the difficulty of translating the SF-36 and the quality of the resulting translation. To assess the psychometric properties of the Australian form, a random sample of people residing in the Hunter region of New South Wales, Australia, were invited to complete the SF-36 with 855 respondents consenting to complete the measure. Principal components analyses supported the assumption of two factors underlying the measure with the percentage of variance explained by these factors ranging from between 0.66 and 0.77. Demonstrable internal consistency (both item and scale) and test-retest reliability were also found.

Entities:  

Mesh:

Year:  1998        PMID: 9817113     DOI: 10.1016/s0895-4356(98)00087-0

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  45 in total

1.  New Australian population scoring coefficients for the old version of the SF-36 and SF-12 health status questionnaires.

Authors:  Graeme Tucker; Robert Adams; David Wilson
Journal:  Qual Life Res       Date:  2010-05-04       Impact factor: 4.147

2.  The case for using country-specific scoring coefficients for scoring the SF-12, with scoring implications for the SF-36.

Authors:  Graeme Tucker; Robert Adams; David Wilson
Journal:  Qual Life Res       Date:  2015-09-28       Impact factor: 4.147

Review 3.  Are factor analytical techniques used appropriately in the validation of health status questionnaires? A systematic review on the quality of factor analysis of the SF-36.

Authors:  Henrica C W de Vet; Herman J Adèr; Caroline B Terwee; François Pouwer
Journal:  Qual Life Res       Date:  2005-06       Impact factor: 4.147

4.  The SF36 Version 2: critical analyses of population weights, scoring algorithms and population norms.

Authors:  Graeme Hawthorne; Richard H Osborne; Anne Taylor; Jan Sansoni
Journal:  Qual Life Res       Date:  2007-02-01       Impact factor: 4.147

5.  SA HealthPlus: a controlled trial of a statewide application of a generic model of chronic illness care.

Authors:  Malcolm Battersby; Peter Harvey; P David Mills; Elizabeth Kalucy; R G Pols; Peter A Frith; Peter McDonald; Adrian Esterman; George Tsourtos; Ronald Donato; Rodney Pearce; Christopher McGowan
Journal:  Milbank Q       Date:  2007       Impact factor: 4.911

6.  The impact of progressive chronic kidney disease on health-related quality-of-life: a 12-year community cohort study.

Authors:  Melanie L R Wyld; Rachael L Morton; Phil Clayton; Muh Geot Wong; Meg Jardine; Kevan Polkinghorne; Steve Chadban
Journal:  Qual Life Res       Date:  2019-04-01       Impact factor: 4.147

7.  Validation and calibration of the SF-36 health transition question against an external criterion of clinical change in health status.

Authors:  Stephanie A Knox; Madeleine T King
Journal:  Qual Life Res       Date:  2009-03-28       Impact factor: 4.147

8.  Equivalence of Chinese and US-English versions of the SF-36 health survey.

Authors:  J Yu; S J Coons; J R Draugalis; X S Ren; R D Hays
Journal:  Qual Life Res       Date:  2003-06       Impact factor: 4.147

9.  The classification systems of the EQ-5D, the HUI II and the SF-6D: what do they have in common?

Authors:  Uwe Konerding; Jörn Moock; Thomas Kohlmann
Journal:  Qual Life Res       Date:  2009-09-01       Impact factor: 4.147

10.  The mental health of young people with disabilities: impact of social conditions.

Authors:  Anne Honey; Eric Emerson; Gwynnyth Llewellyn
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-11-06       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.